6-Bromoindirubin-3′-oxime (PUBCHEM_CID: 448949) targeted PDK1 and EPHX2 in AD (Importance 21.9) and MS (Importance 15.1), with a combined importance of 37.0, affecting carbohydrate and lipid metabolism. This evidence concerns the gene EPHX2 and Alzheimer disease.